Targeted recombinant fusion proteins of IFNγ and mimetic IFNγ with PDGFβR bicyclic peptide inhibits liver fibrogenesis in vivo

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Bansal, Ruchi ^a,b   Prakash, Jai ^a,b   De Ruiter, Marieke ^b   Poelstra, Klaas ^b  

^a UNIVERSITY OF TWENTE   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; GAMMA INTERFERON; HYBRID PROTEIN; NITRIC OXIDE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR BICYCLIC PEPTIDE GAMMA INTERFERON; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR BICYCLIC PEPTIDE MIMETIC GAMMA INTERFERON; STAT1 ALPHA PROTEIN; STAT1 PROTEIN; UNCLASSIFIED DRUG; CARBON TETRACHLORIDE; GAMMA INTERFERON ACTIVATION FACTOR; INTERFERON STIMULATED GENE FACTOR 3; PRIMER DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; COLLAGEN DEGRADATION; CONTROLLED STUDY; DRUG UPTAKE; ESCHERICHIA COLI; FIBRIN FORMATION; IN VITRO STUDY; LIVER FIBROSIS; MACROPHAGE; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTEIN TARGETING; RECEPTOR BINDING; SIGNAL TRANSDUCTION; STELLATE CELL; THROMBOCYTE COUNT; ANALYSIS OF VARIANCE; ANIMAL; CELL CULTURE; CHEMICALLY INDUCED; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; HUMAN; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LIVER CIRRHOSIS; METABOLISM; PLASMID; REAL TIME POLYMERASE CHAIN REACTION; TOXICITY;

ANALYSIS OF VARIANCE; ANIMALS; CARBON TETRACHLORIDE; CELLS, CULTURED; DNA PRIMERS; ESCHERICHIA COLI; FLUORESCENT ANTIBODY TECHNIQUE; HEPATIC STELLATE CELLS; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INTERFERON-GAMMA; INTERFERON-STIMULATED GENE FACTOR 3; LIVER CIRRHOSIS; MICE; NITRIC OXIDE; PLASMIDS; PLATELET COUNT; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RECOMBINANT FUSION PROTEINS;

EID: 84896087944     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0089878     Document Type: Article

References (37)

1. Bonnem EM, Oldham RK (1987) Gamma-interferon: physiology and speculation on its role in medicine. JBiolResponse Mod 6: 275-301. (Pubitemid 18040530)
2. Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, et al. (2007) Interferons at age 50: past, current and future impact on biomedicine. NatRevDrug Discov 6: 975-990. (Pubitemid 350201788)
3. Bouros D, Antoniou KM, Tzouvelekis A, Siafakas NM (2006) Interferon-gamma 1b for the treatment of idiopathic pulmonary fibrosis. ExpertOpinBiolTher 6: 1051-1060. (Pubitemid 44497129)
4. King TE, Jr., Albera C, Bradford WZ, Costabel U, Hormel P, et al. (2009) Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 374: 222-228.
5. Knight B, Lim R, Yeoh GC, Olynyk JK (2007) Interferon-gamma exacerbates liver damage, the hepatic progenitor cell response and fibrosis in a mouse model of chronic liver injury. JHepatol 47: 826-833. (Pubitemid 350064325)
6. Oldroyd SD, Thomas GL, Gabbiani G, El Nahas AM (1999) Interferon-gamma inhibits experimental renal fibrosis. Kidney Int 56: 2116-2127. (Pubitemid 30004740)
7. Miller CH, Maher SG, Young HA (2009) Clinical Use of Interferon-gamma. AnnNYAcadSci 1182: 69-79.
8. Pockros PJ, Jeffers L, Afdhal N, Goodman ZD, Nelson D, et al. (2007) Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis. Hepatology 45: 569-578. (Pubitemid 46450609)
9. Bansal R, Post E, Proost JH, de Jager-Krikken A, Poelstra K, et al. (2011) PEGylation improves pharmacokinetic profile, liver uptake and efficacy of Interferon gamma in liver fibrosis. Journal of controlled release: official journal of the Controlled Release Society 154: 233-240.
10. Cleland JL, Jones AJ (1996) Stable formulations of recombinant human growth hormone and interferon-gamma for microencapsulation in biodegradable microspheres. PharmRes 13: 1464-1475. (Pubitemid 26356947)
11. Gu F, Younes HM, El-Kadi AO, Neufeld RJ, Amsden BG (2005) Sustained interferon-gamma delivery from a photocrosslinked biodegradable elastomer. JControl Release 102: 607-617. (Pubitemid 40170204)
12. Poelstra K, Schuppan D (2011) Targeted therapy of liver fibrosis/cirrhosis and its complications. Journal of hepatology 55: 726-728.
13. Friedman SL (2008) Hepatic fibrosis - overview. Toxicology 254: 120-129.
14. Guo J, Friedman SL (2007) Hepatic fibrogenesis. SeminLiver Dis 27: 413-426. (Pubitemid 350071841)
15. Gressner OA, Weiskirchen R, Gressner AM (2007) Evolving concepts of liver fibrogenesis provide new diagnostic and therapeutic options. Comp Hepatol 6: 7.
16. Popov Y, Schuppan D (2009) Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies. Hepatology 50: 1294-1306.
17. Friedman SL (2004) Stellate cells: a moving target in hepatic fibrogenesis. Hepatology 40: 1041-1043.
18. Friedman SL (2008) Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 88: 125-172.
19. Baroni GS, D'Ambrosio L, Curto P, Casini A, Mancini R, et al. (1996) Interferon gamma decreases hepatic stellate cell activation and extracellular matrix deposition in rat liver fibrosis. Hepatology 23: 1189-1199. (Pubitemid 26137066)
20. Bansal R, Prakash J, Post E, Beljaars L, Schuppan D, et al. (2011) Novel engineered targeted interferon-gamma blocks hepatic fibrogenesis in mice. Hepatology 54: 586-596.
21. Borkham-Kamphorst E, Kovalenko E, van Roeyen CR, Gassler N, Bomble M, et al. (2008) Platelet-derived growth factor isoform expression in carbon tetrachloride-induced chronic liver injury. Lab Invest 88: 1090-1100.
22. Wong L, Yamasaki G, Johnson RJ, Friedman SL (1994) Induction of beta-platelet-derived growth factor receptor in rat hepatic lipocytes during cellular activation in vivo and in culture. JClinInvest 94: 1563-1569.
23. Bansal R, Prakash J, Ruijter M, Beljaars L, Poelstra K (2011) Peptide-modified albumin carrier explored as a novel strategy for a cell-specific delivery of interferon gamma to treat liver fibrosis. Molecular pharmaceutics 8: 1899-1909.
24. Johnson HM, Ahmed CM (2006) Gamma interferon signaling: insights to development of interferon mimetics. Cell MolBiol 52: 71-76. (Pubitemid 43925163)
25. Subramaniam PS, Flowers LO, Haider SM, Johnson HM (2004) Signal transduction mechanism of a peptide mimetic of interferon-gamma. Biochemistry 43: 5445-5454. (Pubitemid 38620936)
26. Xu L, Hui AY, Albanis E, Arthur MJ, O'Byrne SM, et al. (2005) Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut 54: 142-151. (Pubitemid 40007234)
27. Kim YM, Son K (1996) A nitric oxide production bioassay for interferongamma. JImmunolMethods 198: 203-209.
28. Arthur MJ (2000) Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. AmJPhysiol GastrointestLiver Physiol 279: G245-G249.
29. Benyon RC, Arthur MJ (2001) Extracellular matrix degradation and the role of hepatic stellate cells. SeminLiver Dis 21: 373-384. (Pubitemid 32923766)
30. Schafer A, Scheurlen M, Seufert J, Keicher C, Weissbrich B, et al. (2010) Platelet serotonin (5-HT) levels in interferon-treated patients with hepatitis C and its possible association with interferon-induced depression. JHepatol 52: 10-15.
31. Bataller R, Brenner DA (2005) Liver fibrosis. JClinInvest 115: 209-218. (Pubitemid 40385459)
32. Schuppan D, Afdhal NH (2008) Liver cirrhosis. Lancet 371: 838-851. (Pubitemid 351323895)
33. Ahmed CM, Burkhart MA, Mujtaba MG, Subramaniam PS, Johnson HM (2003) The role of IFNgamma nuclear localization sequence in intracellular function. JCell Sci 116: 3089-3098. (Pubitemid 37038958)
34. Ghosh AK, Bhattacharyya S, Mori Y, Varga J (2006) Inhibition of collagen gene expression by interferon-gamma: novel role of the CCAAT/enhancer binding protein beta (C/EBPbeta). J Cell Physiol 207: 251-260.
35. Beljaars L, Weert B, Geerts A, Meijer DK, Poelstra K (2003) The preferential homing of a platelet derived growth factor receptor-recognizing macromolecule to fibroblast-like cells in fibrotic tissue. BiochemPharmacol 66: 1307-1317. (Pubitemid 37130306)
36. Farrar MA, Schreiber RD (1993) The molecular cell biology of interferongamma and its receptor. AnnuRevImmunol 11: 571-611. (Pubitemid 23115018)
37. Beljaars L, Molema G, Schuppan D, Geerts A, De Bleser PJ, et al. (2000) Successful targeting to rat hepatic stellate cells using albumin modified with cyclic peptides that recognize the collagen type VI receptor. The Journal of biological chemistry 275: 12743-12751. (Pubitemid 30241427)